Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Faye Sharpley"'
Autor:
Yvette Ibbotson, Dane Bradwell, Roxanne Spencer, Simon Jowitt, Faye Sharpley, Hannah Miller, Janet Parkinson
Publikováno v:
Hemato, Vol 2, Iss 40, Pp 628-634 (2021)
In the UK, approximately 5820 new cases of multiple myeloma (MM) are diagnosed each year. This number has increased by a third since the early 1990s. Considerable progress has been achieved in our ability to treat MM as a result of the development of
Autor:
Richa Manwani, Shameem Mahmood, Faye Sharpley, Philip N. Hawkins, Aviva Petrie, Oliver C Cohen, Ana Martinez De Azcona Naharro, Julian D. Gillmore, Marianna Fontana, Helen J. Lachmann, Sajitha Sachchithanantham, Carol J. Whelan, Ashutosh D. Wechalekar
Publikováno v:
European Journal of Haematology. 106:537-545
Objectives The benefit of autologous stem cell transplantation (ASCT) in the treatment of light chain (AL) amyloidosis requires re-evaluation in the modern era. This retrospective case-matched study compares ASCT to bortezomib for the treatment of pa
Autor:
Carol J. Whelan, Dorota Rowczenio, Marianna Fontana, Richa Manwani, Ana Martinez-Naharro, Helen J. Lachmann, Julian D. Gillmore, Sajitha Sachchithanantham, Shameem Mahmood, Tamer Rezk, Faye Sharpley, Philip N. Hawkins, Ashutosh D. Wechalekar, Janet A. Gilbertson, Cristina Quarta
Publikováno v:
Transplantation. 104:415-420
Background Development of amyloidosis post solid-organ transplantation has not been reported, although plasma cell neoplasms are a rare form of posttransplant lymphoproliferative disorder, which could be complicated by light chain amyloidosis (AL) am
Autor:
Ashutosh D. Wechalekar, Carol J. Whelan, Charalampia Kyriakou, Ana Martinez-Naharro, Neil Rabin, Raakhee Shah, Sajitha Sachchithanantham, Shameem Mahmood, Julian D. Gillmore, Simon Cheesman, Faye Sharpley, Philip N. Hawkins, Kwee Yong, Oliver C Cohen, Helen J. Lachmann, Marianna Fontana, Rakesh Popat
Publikováno v:
British Journal of Haematology. 189:643-649
With improving outcomes in amyloid light-chain (AL) amyloidosis, there is a need to study novel agents in this setting. We report outcomes of 40 patients with relapsed AL amyloidosis treated with ixazomib + lenalidomide + dexamethasone (IRd). Haemato
Autor:
Isobel Ramsay, Ana Garcia Mingo, Shameem Mahmood, Atul Mehta, Faye Sharpley, Dunnya De-Silva, Charalampian Kyriakou, Sajitha Sachchithanantham, Ashutosh D. Wechalekar, Paul D. Griffiths, Derralynn Hughes, Sarah Worthington
Publikováno v:
European Journal of Haematology. 104:230-235
Objective Cytomegalovirus (CMV) is an opportunistic herpesvirus, and reactivation of infection is possible in immunocompromised patients. Historically, the risk for haematology patients is restricted to those treated with an allogeneic transplant or
Autor:
Darren Foard, Sajitha Sachchithanantham, Cristina Quarta, Shameem Mahmood, Faye Sharpley, Philip N. Hawkins, Oliver C Cohen, Richa Manwani, Helen J. Lachmann, Carol J. Whelan, Marianna Fontana, Julian D. Gillmore, Ashutosh D. Wechalekar
Publikováno v:
Blood. 134:2271-2280
Bortezomib is a standard therapy in light-chain amyloidosis (AL), but little is known about response duration. A difference in involved amyloidogenic and uninvolved serum-free light chains (dFLC)10 mg/L (low dFLC response) predicts survival in AL pat
Autor:
Samih Fourali, John A Lynes, Karthik Ramasamy, Jaimal Kothari, Faye Sharpley, Susan McLain-Smith, Faouzi Djebbari
Publikováno v:
Leukemia & Lymphoma. 61:732-736
Despite recent approval of lenalidomide by The National Institute for Health and Care Excellence (NICE), fixed-duration therapy (FDT) with thalidomide or bortezomib plus an alkylating agent and ste...
Autor:
Shameem Mahmood, Ana Martinez-Naharro, Helen J. Lachmann, Cristina Quarta, Faye Sharpley, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana, Aviva Petrie, Sajitha Sachchithanantham, Carol J. Whelan, Ashutosh D. Wechalekar
Publikováno v:
British Journal of Haematology. 187:642-652
Autologous stem cell transplantation (ASCT) is considered to be the best method to achieve deep haematological/organ responses and improve survival in selected patients with AL amyloidosis. This field has been led by US centres and is less utilised i
Autor:
Sajitha Sachchithanantham, Dorota Rowczenio, Candida Cristina Quarta, Ana Martinez-Naharro, Joan Caringal-Galima, Marianna Fontana, Harvey Jenner, Ottavia Bertolli, Richa Manwani, Shameem Mahmood, Alan Calleja, Faye Sharpley, Philip N. Hawkins, Aviva Petrie, Julian D. Gillmore, Edmund Drage, Thirusha Lane, Janet A. Gilbertson, David F. Hutt, Carol J. Whelan, Ashutosh D. Wechalekar, Tamer Rezk, Rosie McDonald, Svetla G. Strehina, Helen J. Lachmann
Publikováno v:
Circulation
Background: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients
Autor:
Julian D. Gillmore, Sajitha Sachchithanantham, Marianna Fontana, Richa Manwani, Philip N. Hawkins, Carol J. Whelan, Helen J. Lachmann, Ashutosh D. Wechalekar, Shameem Mahmood, Faye Sharpley
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 2, Pp 1-4 (2019)
Blood Cancer Journal
Blood Cancer Journal